- Biosciences and diagnostics company Enzo Biochem Inc ENZ reported fourth-quarter FY21 revenue growth of 27% year-on-year to $24.8 million. Revenue decreased 24% sequentially.
- The results reflect strong product sales, moderated by a slow-down in COVID-19 testing during the summer months.
- Segments: Enzo Clinical Lab revenue increased 30% Y/Y to $16.8 million. Enzo Life Sciences revenue was $8.1 million, up 38% Y/Y.
- Margin: The consolidated margin remained stable at 40%.
- Non-GAAP EPS was $0.07 versus $(0.07) in the year-ago quarter.
- Selling, general and administrative expenses for the quarter increased 18% to $11.8 million.
- Enzo Biochem held $43.5 million in cash and equivalents.
- Price Action: ENZ shares traded lower by 2.93% at $3.97 in the premarket session on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in